Precipio

Company Snapshot

Founded: 2017
Entity Type: Public
Employees: 61
Region: U.S.
Revenue: $24.0 Millions
Revenue Year: 2025
Headquarter: Connecticut, U.S.
Key Geographics: U.S.
Corporate Address: 4 Science Park, New Haven Connecticut 06511 U.S. Tel. +1-203-787-7888 www.precipiodx.com

Company Overview

Precipio Inc. is developing liquid biopsy-based diagnostics products and services for cancer applications. In October 2016 Precipio merged with Transgenomic and integrated the two companies’ operations.

Precipio uses BLOCker sequencing that increases the sensitivity for certain mutations. The firm also offers a mutation enrichment platform called ICE Cold-PCR (ICP), which can be combined with blocking oligonucleotides in cycle (BLOCker) sequencing to achieve very low detection limits on Sanger platforms.

In BLOCker sequencing, a locked nucleic acid (LNA) is inserted into the oligonucleotide. This blocks wild-type DNA to be sequenced at specific positions while permitting mutated DNA to be sequenced at the same position. During the Sanger sequencing cycle, the blocking oligo is added and anneals to the template. During the cycle, the temperature is increased, causing the oligo to separate from the mutated DNA, but remain annealed to the wild-type DNA. The oligo remains attached to the wild-type DNA, so it cannot be sequenced.

Precipio operates a CLIA laboratory in New Haven, Conn., and in 2017 launched a redesigned ICP target enrichment kit to identify mutations in lung cancer using liquid biopsies.

In May 2018 Precipio launched its ICP KRAS liquid biopsy kits for pancreatic cancer. The kits are available in both qPCR and Sanger sequencing platforms and use the ICP technology. The target market for these kits is as enrichment technology for laboratories developing screening and monitoring tests.

In November 2018 Precipio formed an alliance with PerkinElmer covering liquid biopsy test development and using Precipio’s ICP platform.

Financial Highlights (FY 2025)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Precipio In Reports

Global DNA Read, Write and Edit Market

The global market for DNA read, write and edit applications should grow from $17.0 billion in 2019 to $43.1 billion by 2024 with a compound annual growth rate of 20.5% during the period of 2019-2024.

Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023

Get an overview of the global markets for liquid biopsy technologies, applications, industry subsegments along with analyses of global market trends with data from 2017, 2018 and projections of CAGRs through 2023 ...

Global DNA Sequencing: Research, Applied and Clinical Markets

The global DNA sequencing market was $10.7 billion in 2018 and is forecast to increase at a compound annual growth rate of 18.0% to reach $24.4 billion in 2023.

Company's Business Segments

  • Service : This segment includes Medicaid, Medicare, Self-pay, Third Party Payers, Contract Diagnostics and Others.
  • Product : This segment includes Molecular Kits, MPN Panel, BCR-ABL1 Panel, ABL1 Resistance Panel, AML Panel, CLL Panel, Cytopenia Panel

Applications/End User Industries

  • Hematopathology Services
  • Bloodhound MPN
  • HemeScreen Reagents
  • Hospitals
  • Healthcare
AI Sentiment